A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Phase 1

Completed

• Conditions: Chronic Rhinosinusitis With Nasal Polyps
• Interventions: Drug: CM326; Other: Placebo

• Registration Number: NCT05324137
• Lead Sponsor: Keymed Biosciences Co.Ltd

Brief Summary

This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis with nasal polyps.

Detailed Description

The study consists of 3 periods, a Screening Period, a Treatment Period and a Safety Follow-up Period.

Subjects who meet eligibility criteria will be randomized to receive either CM326 or placebo subcutaneously.

Study Timeline

• Study First Submitted: 2022-03-18
• Study First Submitted QC: 2022-04-05
• Study First Posted: 2022-04-12
• Study Start: 2022-07-11
• Status Verified: 2024-03
• Primary Completion: 2024-03-29
• Study Completion: 2024-03-29
• Last Update Submitted: 2024-11-07
• Last Update Posted: 2024-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

• Subjects who are capable of understanding the nature of the study and voluntarily signing the ICF.
• Male or female subjects, aged between 18 and 70 years old (inclusive), with a body mass index (BMI) ≥ 19 kg/m2.
• Diagnosed with Chronic Rhinosinusitis With Nasal Polyps.
• The total NPS score should be at least 3 points, with at least 1 point in each side of the nasal cavity.
• Prior treatment with systemic corticosteroids (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening.
• Ongoing symptoms for at least 4 weeks before screening：1) Nasal congestion/obstruction; 2) Other symptom, e.g., loss of smell or rhinorrhea.

Exclusion Criteria

• Allergic or intolerant to mometasone furoate spray or CM326/placebo.
• Have used of systemic immunosuppressants for inflammatory or autoimmune diseases within 8 weeks or 5 half-lives prior to randomization.
• Have initiated leukotriene receptor antagonist therapy within 4 weeks prior to randomization.
• have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period.
• Have undergone nasal surgery (including nasal polypectomy) within 6 months prior to screening.
• Have received medium- and short-acting systemic corticosteroids (including oral, intravenous, intramuscular corticosteroids), nasal dripping corticosteroids, traditional Chinese medicine (including systemic and local herbal products preparations) for chronic rhinosinusitis (CRS) within 4 weeks prior to screening, or long-acting systemic corticosteroids.
• With concomitant asthma (including suspected diagnosis of asthma) will be excluded if they meet the following conditions: predicted FEV1 of≤ 60%, or acute exacerbation of asthma within 3 months prior to screening requiring SCS or hospitalization (> 24 hours), or using inhaled corticosteroids (ICS) of > 1000 μg fluticasone propionate or others at equivalent doses
• With antrochoanal polyps.
• With severe deviation of the nasal septum occludes at least one nostril.
• With persistent rhinitis medicamentosas.
• With allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, cystic fibrosis.
• With acute sinusitis, nasal infection, or upper respiratory tract infection at screening.
• Have symptoms or whose CT scan suggests allergic fungal sinusitis.
• With malignant or benign neoplasm of nasal cavities.
• With other uncontrolled serious diseases or recurrent chronic diseases.
• Have severe hepatic and renal impairment.
• Have received live attenuated vaccines within 12 weeks prior to randomization, or during the planned study; or have received inactivated vaccines (e.g., novel coronavirus vaccines) within 30 days prior to randomization.
• With known or suspected immunosuppression, including, but not limited to, the history of invasive opportunistic infections.
• Subjects who are pregnant or planning to become pregnant, or breastfeeding during the study.
• With a history of large alcohol consumption or a history of drug abuse within 3 months prior to screening.
• With other medical or non-medical conditions that are not suitable for participation in the study in the opinion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Group 3: 220mg Q2W	CM326	CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 2: 110mg Q2W	CM326	CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 4: 220mg Q4W	CM326	CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)
Group 1: 55mg Q2W	CM326	CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 1: 55mg Q2W	Placebo	CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 2: 110mg Q2W	Placebo	CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 3: 220mg Q2W	Placebo	CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)
Group 4: 220mg Q4W	Placebo	CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)

Primary Outcome Measures

Name	Time	Method
Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.	up to Week 64	Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16.	at week 16	NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

Secondary Outcome Measures

Name	Time	Method
Immunogenicity: anti-drug antibody (ADA)	up to Week 64	Occurrence of positive anti-drug antibody (ADA)
PD: Changes from baseline in serum periostin after CM326 administration	up to Week 64	Changes from baseline in serum periostin after CM326 administration
PD: Changes from baseline in plasma interleukin-5 (IL-5) after CM326 administration	up to Week 64	Changes from baseline in plasma interleukin-5 (IL-5) after CM326 administration
PK: Concentration of CM326 in plasma	up to Week 64	Concentration of CM326 in plasma
PD: Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration.	up to Week 64	Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration.
PD: Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration.	up to Week 64	Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration.
PD: Changes from baseline in blood eosinophilic level after CM326 administration	up to Week 64	Changes from baseline in blood eosinophil level after CM326 administration
PD: Changes from baseline in eosinophilic level of nasal polyp biopsy tissue after CM326 administration	up to Week 64	Changes from baseline in eosinophil level of Nasal polyp biopsy tissue after CM326 administration
Efficacy: changes from baseline of nasal polyp score (NPS) in non-eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP)	up to Week 64	NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.
PD: Changes from baseline in plasma interleukin-13 (IL-13) after CM326 administration	up to Week 64	Changes from baseline in plasma interleukin-13 (IL-13) after CM326 administration

Trial Locations

Locations (1)

Beijing Tongren Hospital, CMU; 🇨🇳 Beijing, Beijing, China